1 – 10 of 23
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling
(
- Contribution to journal › Article
-
Mark
Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab
(
- Contribution to journal › Article
- 2023
-
Mark
#898 Tumor-informed ctDNA detection as a marker for postoperative residual disease in epithelial ovarian cancer : results of a feasibility study
(
- Contribution to journal › Published meeting abstract
-
Mark
805P Tumor-informed ctDNA detection as a predictive marker for postoperative residual disease in epithelial ovarian cancer: A feasibility study
(
- Contribution to journal › Published meeting abstract
-
Mark
Preoperative ctDNA Levels Are Associated With Poor Overall Survival in Patients With Ovarian Cancer
(
- Contribution to journal › Article
-
Mark
Abstract 5710: Detection and monitoring of t(11;14) in liquid biopsies from patients with relapsed/refractory multiple myeloma treated with venetoclax-based regimens
(
- Contribution to journal › Published meeting abstract
- 2022
-
Mark
Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors
(
- Contribution to journal › Article
-
Mark
Preoperative circulating tumor DNA level is associated to poor overall survival in patients with ovarian cancer
(
- Contribution to journal › Published meeting abstract
- 2021
-
Mark
Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer
(
- Contribution to journal › Article
- 2020
-
Mark
Abstract CT074: Pre-existing ESR1 mutations in early-stage primary breast cancer predict failure of endocrine therapy and poor survival
(
- Contribution to journal › Published meeting abstract